<?xml version="1.0" encoding="UTF-8"?>
<p>First, it can be a matter of time. The time at which the COVID-19 patient develops the pathologic hyperactivation of the immune response, eventually contributing to the final injury, is probably in the late phase of the disease manifestation, occurring together with the respiratory distress [
 <xref rid="B17" ref-type="bibr">17</xref>]. Furthermore, the time matters also in the case of ICI therapy, since the majority of patients develop irAEs within the first 6 months from the first administration [
 <xref rid="B12" ref-type="bibr">12</xref>]. Thus, a certain caution for ICI administration during the pandemics could be applied mostly for those patients needing therapy initiation or in their first months of treatment.
</p>
